Navigating the opaque drug rescheduling petition process under the Controlled Substances Act

Researchers, patient advocates, and pharmaceutical companies struggle to understand and successfully petition the DEA for drug rescheduling because the process lacks clear procedural guidance, transparent criteria, and predictable timelines. Current solutions fail because the CSA's rescheduling mechanism is poorly documented, politically contentious, and requires specialized legal expertise that's expensive and difficult to access, leaving many with potentially beneficial drugs stuck in restrictive schedules.